Note: This is a preliminary transcript and may contain inaccuracies. It will be updated with a final, fully-reviewed version soon.
Sakar Healthcare Ltd (NSE: SAKAR) Q4 2026 Earnings Call dated May. 15, 2026
Corporate Participants:
Pushpa Ponmany — Manager
Bikramjit Ghosh — Vice President, Strategy and Business Development
Analysts:
Nikunj Seth — Analyst
Rupesh Tatiya — Analyst
Avnish Burman — Analyst
Unidentified Participant
Harsh Pradhan — Analyst
Vedant Madan — Analyst
Ankit Gupta — Analyst
Ishit Desai — Analyst
Presentation:
Operator
Ladies and gentlemen, good day and welcome to Sakhar Healthcare Limited Q4FY26 earnings conference call. As a reminder, all participant lines will be in the listen only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing Star then zero on your touchstone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Nikun Seth from MUFG in time.
Thank you. And over to you sir.
Nikunj Seth — Analyst
Thank you. Welcome to Sakaar Healthcare Q4FY26 earnings call today. On the call we have Mr. Vikramjit Ghosh, Vice President Strategy and Business Development, Mr. Dharmesh Thakkar, CFO, Mr. Bharat Soni, Company Secretary and Ms. Pushpa. Before we proceed with the call, I would like to give a small disclaimer that the call may contain certain forward looking statements which are based on the business opinions and expectations of the company as on date. A detailed disclaimer has been given in the company’s investor presentation which is uploaded on the stock exchange.
Now I would like to hand over the call to Ms. Pushpa. Over to you Merka.
Pushpa Ponmany — Manager
Good morning. I welcome all our shareholders, investors and analysts to the earnings call of Sakar Healthcare Limited for the quarter and financial year ending 31st March 2026. Over the last few years, Sakhar Healthcare has consciously invested in building a dedicated oncology platform. This platform brings together oncology API, finished formulations, R and D capabilities and globally compliant manufacturing infrastructure. These investments were made with a clear objective to transform Sarka from a diversified pharmaceutical manufacturer into a focused specialty on quality company with exports as the primary growth driver.
The benefits of these investments are now beginning to materialize. Progress on regulatory approvals, technology transfers and customer validations along with a steady rise in export orders have started translating into tangible commercial momentum. Quarter four marked a significant milestone in this journey with oncology exports gaining traction and profitability improving bringing the company closer to its long term vision of becoming a pure play export led oncology player. The EU GNP approved oncology facility at Bawla, Gujarat is API integrated and designed to serve regulated global markets.
It can manufacture complex oncology products across oral liquids, oral solids, injectable oral liquids and APIs supported by advanced containment systems, formulation development, analytical capabilities and flow chemistry infrastructure. During the year we achieved an important milestone with the approval to manufacture imats IMIT for Accord Healthcare UK for supplies into Europe. This validation is a strong endorsement of our quality systems compliance standards and manufacturing capabilities.
It also establishes Saka as a credible partner for global oncology companies looking for reliable manufacturing and supply from India. Our oncology business is now entering the scale up phase. We have already signed more than 60 oncology business contracts with over 35 discussions currently ongoing. Out of 250 Dolios shared globally, 125 had been filed and 12 have received marketing authorization. Across our developed oncology portfolio, 11 approvals have been received for key molecules including imatinib, abiraterone, capacitabine, gemcitabine, carboplatin, Irinotican and doxytisil.
In addition, technology transfer projects are underway with partners such as Accor, Intel, Torrent, mcure, Glenmark and Zydus. With site variation approval already received in the UK and EU. The Accord Intact portfolio alone comprising 10 oncology products to be manufactured by Saka represents a potential opportunity of Rupees 50 crore to 100 crore depending on the commerce specialization strategy. Across Europe, commercial exports to regulated markets are expected to commence in phases with Europe likely to be the initial focus market.
At the same time, oncology exports are already underway to markets such as the uk, Mauritius, Lebanon, Algeria and several African countries. Going forward, oncology is expected to become the core growth engine of Sakhar healthcare. In financial 2026, the oncology division contributed around 38% of total revenues. While the current mix is balanced between domestic and export markets, we expect exports to become the dominant contributor to over the medium term as more approvals convert into commercial supplies.
Our focus will remain on three key priorities increasing dose year approvals, deepening international partnerships and scaling product launches across regulated and emerging markets. Over the next two years we aim to cross 300 dossier approvals, achieved more than 100 overseas business contracts and built a strong base of marketing authorizations. The scalability of this platform is one of our biggest trends. The Baala oncology facility designed for large scale operations is expected to scale up over the next four to five years and can potentially generate revenues of Rupees 800 crore to 1000 crore at optimal utilization without requiring significant incremental capex.
Since current utilization remains low, there is substantial room for operating leverage as export volumes scale up. Given the higher margin nature of oncology products, we expect EBITDA margins in this division to remain in the range of 25% to 30 over the medium term. While oncology will remain our primary strategic focus, our CDMO and non oncology business continue to provide stability, cash flows and strong customer relationships. We continue to manufacture leading pharmaceutical companies such as Zydis, mcure, Glenmark, cipla, IPCA and ABOUT across multiple dosage forms including oral liquids, tablets, injectable dry powder formulations and inhalers.
Our Changozal facility continues to support the nonalcoholity business while our broader portfolio includes liquid and lipolyzed injectable oral solids and liquids, exports of saccharin, heparin based formulations, cephalosporins and other products. Our branded formulations business is also expanding across apac, Latin America, cis, Africa and select European markets. We were also pleased to be recognized by the Ethiopian Pharmaceutical Supply Services as one of the best supplies for 20242025 which reflects our improving credibility and execution in international markets.
Now coming to the Financial performance for quarter four and financial year 2026 Consolidated results for quarter four financial year 2026 Revenue from operations stood at Rupees 7109.70 lakh compared to Rupees 5024.18 lakhs in quarter four financial year 2025 reflecting a robust 42% year on year growth. EBITDA for the quarter was Rupee 2623.57 lakhs compared to Rupees 15.72.47 lakh in quarter four financial year 2025, an increase of 67% year on year with EBITDA margins at 37% profit after tax to death Rupees 1102.43 lakhs compared to INR 576.11 lakhs in quarter four financial year 2025 delivering a strong 91% year on year growth supported by our oncology division, operational leverage and cost discipline.
Gross margins remained healthy at 60% driven by improved efficiency and scale benefits across our oncology vertical. For the year ended financial year 2026, the revenue stood at rupees 25173.60 lakhs as against rupees 1775 8.47 lakhs in financial year 2025 reflecting a 20 to 42% year on year increase. EBITDA in financial year 2026 was INR 6888.82 lakhs compared to INR 4968.32 lakhs in the financial year 2025, an increase of 39% year on year. Profit after tax for financial year 2026 was rupees 3048.46 lakhs compared to rupees 1750.20 lakhs in the financial year 2025 reflecting a 74% year on year growth overall.
The strong financial and operational performance reflects the scalability of our integrated oncology platform, the growing acceptance of our manufacturing quality by global partners and the long term opportunity emerging from our oncology led export strategy. Before I conclude I would like to thank Our Managing Director Mr. Sanjay Shah, our management team, our dedicated employees and our global partners for their continued commitment and contribution. I also extend my gratitude to all shareholders and analysts for their continued trust and support in Sakar Healthcare’s journey.
Thank you for your time. We will now open the floor for questions.
Questions and Answers:
Operator
Thank you very much. We will now begin the question and answer session. Anyone who wishes to ask a question may press star and one on the touchtone telephone. If you wish to remove yourself from the question queue you may press star and two participants are requested to use answers while asking a question. We also request participants to please limit their question to two per participant. Ladies and gentlemen, we will wait for a moment while the question queue assembles. The first question is from the line of Rupesh Tatiya from Long Equity Partners.
Please go ahead.
Rupesh Tatiya
Thank you. Thank you for the opportunity sir and congratulations on fantastic set of numbers. I must congratulate you for giving you know very realistic guidance and then meeting it. My first question sir is on the I think next year we have you know aspiration of going to 380 crore revenue. Do you, do you still hold on to that guidance considering you know whatever is happening in the world, crude oil prices, raw material prices going up, so much disruption in shipping and all that. So how are you looking at FY27?
Do we still hold on to the 380 crore guidance?
Bikramjit Ghosh
Yeah. Thank you so much for sharing your wishes. And it’s indeed a achievement for us as well. Particularly the oncology setup is giving us, turning us to be now revenue generating for us. Yes indeed we are looking forward to for the year of year over year growth with the same momentum which we have picked up this year. Means if you see we have already registered 42% this year and we wanted to hold in the similar line for the next financial year where also I have told earlier that oncology will be the main driving force in that considering the infrastructure or setup, what we are building up in terms of our doji’s, in terms of our product development and in terms of our registrations worldwide.
Rupesh Tatiya
So just to Summarize you still expect 40% type of growth next year also if. Yeah,
Bikramjit Ghosh
That is that we are actually eyeing for. For the next financial year with the entire set of reading taking off.
Rupesh Tatiya
Okay. Okay. And then the second question sir is you. You said this ator partnership has 100 crore revenue potential. So how much of that was realized in FY26 and how can we see full revenue potential can be realized in FY27?
Bikramjit Ghosh
Yeah, actually if you have gone earlier, whatever has been briefed about in terms of accord we have nine different molecules and 12 sqs which have been undertaken sir. Out of which two already have been done. And based on that we have generated the sales in terms of Accord export. So the full potential has not been tapped in the last financial year which we are expecting to come up this year. So the potential which we are looking forward to is multiple of that and that ranges between 50 to 100 crore depending upon the partners reach within the territory of EU and the uk.
So absolutely you are right that this potential is going to come from Accords end the business in terms of Accord export this financial year with the nine molecules.
Rupesh Tatiya
Okay. Okay. And. And can you maybe like just to follow. Is this a follow up to this question? One clarification. So for other. Other partners, right? Torrent, Glenmark, Zidas and mqr. So. So maybe all of them put together. What is the revenue potential of the rest of the partners? I mean I. We know Accord is a very big player in the Euro. But how about other players? What kind of revenue potential? We are looking at
Bikramjit Ghosh
Revenue potential. That is what I mentioned. In terms of growth means. We are looking forward for Oncology to almost doubling the sale in the next year. That is what we are aspiring for. Considering the infrastructure of what we have built in terms of overseas and as well as the partners which you have rightly mentioned. The zidus, Interst, Glenmark NPO and we have another 1314 domestic players who are adding up to the sales. So that will add up to this overall business growth. What we are looking forward to.
Rupesh Tatiya
Okay. Okay. Thank you for answering my question sir. I’ll come back in the K.
Operator
Thank you. Ladies and gentlemen. In order to ensure that the management is able to address questions from all participants we would request you to please limit your question to two per participant. The next question is from the line of Avnish Tiwari from Waikarna. Please go ahead.
Avnish Burman
Hi. How much was the export oncology revenue in fourth quarter and fiscal 26 and how much are you budgeting for FY27.
Unidentified Participant
Yes. So the fourth quarter export revenue from the oncology business was around 30 lakh rupees. Which in comparison to the last quarter year on year basis in FY25 was 22 lakhs. So there has been a growth in the exports in the ontology segment. And in terms of the business that we have in that the export turnover was around 29 crores. In comparison to the last quarter the of FY25 was 26 crores. And we seemed as said by Mr. Vikram Read, FY27 we are expecting a substantial growth in the exports based on the pipeline that has been created.
Avnish Burman
So there’s 30 lakhs you said, right. For full quarter last quarter. Yeah. Export in onco.
Unidentified Participant
Yes.
Avnish Burman
How much are the domestic oncology revenue in fourth quarter? And how much are you budgeting for next full year?
Unidentified Participant
The last quarter revenue in oncology Domestic is 31 crores. And it would be almost in same lines, probably more than this in the year to come. Quarter on quarter basis.
Avnish Burman
Okay, thank you.
Operator
Thank you. The next question is from the line of Hitendra Pradhan from Maximilian Capital. Please go ahead.
Harsh Pradhan
Yeah. Hi sir. Thanks for the opportunity and hope I’m audible. So just to again you know, confirm the numbers. So for us the onco versus non onco. If we can give the silence for Q4 and FY26 and the oncology exports, you mentioned it was 30 lakhs in Q4. Right. I mean and we expect the revenue potential to be 55 to 100cr over next three years for the nine molecules. If you can confirm that, that would help.
Rupesh Tatiya
Right.
Harsh Pradhan
And so what will be the encore versus non onco? Like overall like our like revenue split?
Bikramjit Ghosh
The revenue
Harsh Pradhan
Revenue Revenue split. Yes. Okay. This year
Bikramjit Ghosh
The noncology noncology is around 62% contribution. Whereas the oncology contributed to 38% of the total revenue. In comparison to the last financial year where it was oncology was only contributing 21% of the total revenue. So this year it is 38%.
Unidentified Participant
And for Q4, sir, Q4, what was the number absolute number in Q4? The absolute number for the oncology business was 31 crores 46 lakhs. And non oncology was 39 crores 64 lakhs. The export portion was still less but we expect it to pick up. Yeah,
Avnish Burman
That
Unidentified Participant
Is specific to this quarter. It is not an overall trend but specific to this quarter answer on the grass.
Operator
May we request you to please rejoin the queue sir. We have participants waiting for the turn.
Unidentified Participant
Oh,
Operator
Thank you. The next question is from the line of Vedantilekar from ICICI securities. Please go ahead.
Unidentified Participant
Hello. Hi. Am I audible?
Operator
Yes, you are. Please go ahead.
Unidentified Participant
Thank you for the opportunity and congratulations to the. For the great set of numbers. So my first question is on the thousand crore. 802,000 crore long term revenue guidance that we have given up in the starting remarks. By when can we. By when are we looking to achieve it and what will be the key drivers for it?
Operator
I’m sorry to interrupt sir, we are unable to hear you.
Avnish Burman
Hello.
Bikramjit Ghosh
Hello. Can you hear?
Operator
Yes. Now please go ahead. Yes sir.
Bikramjit Ghosh
Yeah, yeah. Coming back to your query it is basically as we have been pitching earlier also the oncology is the driving force for moving ahead for us. And you can see the means encouragement what we are receiving from the business revenues what we are getting over year over year in the past couple of years. So what we are looking forward to is almost doubling the sale of oncology in the the coming two years. So that we can initially reach a milestone of around 500 crore first comprising of both the units.
So that is the first milestone we are looking forward to maybe covering up in next two years.
Unidentified Participant
Okay sir. And my second question is on the capacity utilization. If you would please share the capacity utilization for the Onco plant and how it is expected to scale up in the next two years.
Bikramjit Ghosh
The oncology plant capacity utilization is still under 30% absolute will be around 20, 29% plus. So the thing is that this is principally as you can understand from the previous answers that it is predominantly the domestic business which is right now contributing for oncology. Now with the per unit cost built up with the exports with the oncology products. So you can see that this ramp up with the business will increase the capacity utilization accordingly and we can increase to around 50 to 55% with around in the next couple of two years what we are projecting in terms of revenue to match up for that.
Operator
Okay, thank you to please rejoin the queue sir.
Vedant Madan
Yes sir.
Operator
Thank you. The next question is from the line of Ankit Gupta from Bamboo Capital. Please go ahead.
Ankit Gupta
Yeah. Thanks for the opportunity and congratulations for a good set of numbers. Sir, my first question was on the growth that we are expecting in the oncology. You know we are expecting from around 9,500 crore this year. We are planning to reach 200 crore sales in FY27. So will the growth be be equally divided in the coming few quarters or it will be like back ended? Because the. I think the tech transfer revenues for and Accord products is yet to start. So how should we see, you know, the growth spread out across the next coming few quarters for oncology segment.
Bikramjit Ghosh
In that case, I feel a brief background of the current setup. What we have built up maybe in the last couple of years will help. So as you rightly mentioned, the tech transfer projects are about to pick up from the first quarter only of a 527th. So it has already started even in this quarter one with four right now tech transfer projects approved for Europe and the uk, two from Accord, two from. Sorry, five are actually there, two from Accord, two from UK Germany, both Torrent and another company from the uk.
So there are five technical project for which we are right now commercializing the product from the quarter one. Apart from that, as I mentioned, there are total nine projects or nine products there for Accord which are set to get added along with that. And apart from that we have another couple of tech transfer projects which are currently going on in our plant with companies like Glenmark and Incure. So those will added up to that. So this is the technology transfer project which will start gearing up maybe from the quarter two or quarter three of this year.
Along with that we have already set up a robust in terms of submission of dossiers which is roughly accounting Right now around 130plus dossiers submitted in different regions across the world, which includes the Europe as well as Australia, as well as other emerging markets like Africa, Southeast Asia and Latin American markets. So these 130 plus dossiers will transform into marketing authorization or registration of the product so that it can be supplied which will start coming from the quarter two already it has started as already mentioned earlier that we have received two.
We are in the process of commercializing those products from quarter one only because there are a number of processes which needs to be followed before we go for commercialization, particularly to the stringent market. But having said that, we have another 220 dossiers which has already been shared with the partnership. So that makes up a total figure of 300 plus dojos which we are looking forward to in next two years to get converted into active registration so that we can supply the product to the overseas market in terms of exports of oncology product.
So this is basically the background I feel will give you the setup. What we currently have 300 registrations or product dojas going into the market will transform into registration in one hand technology transfer from this big multinationals like Zidus in Task, Landmark, MQR and other local players. So I feel so this is a wide good mix in terms of exports and Import, domestic and we expect that next year it will be almost neck to neck in terms of domestic and export in terms of sales. Considering this, export registrations will convert into commercial supplies.
Ankit Gupta
Okay, so my question was like from Q1, Q2 onwards, should we start seeing a run rate of around 5,40 crore in the oncology setting and then you know it will increase to 50, 60 crore from Q2 onwards. Or it will be like how should we see the growth for oncology in the coming few quarters
Bikramjit Ghosh
In exports? Basically as I told you, there are a number of sequences which needs to be followed and it does not follow a simple pattern of that. It has to be offtake will be there every alternate mand or any quarter. So it may happen that the inter offtake for a year may happen at one go. And particularly oncology is a product where it goes for tender supplies also. So that gives a full view of maybe a full take offtake will happen in quarter three only. So it is very difficult to right now actually set the pattern in terms of that quarter over quarter we will be growing on this percent.
But having said that, what I have told you somewhere or the other, the business will be definitely coming up in terms of product registration or maybe a tech transfer project. Apart from that we are already supplying some domestic players which is the backbone since last two, three years because they are already giving a standard sale of around maybe 30% or 20% of the business what we are registering in terms of domestic. So I feel. So from quarter two basically you can see outflow of or offtake of export business.
But exact pattern is very difficult to comment right now.
Ankit Gupta
Second question was on the margins. If you look at it, you know, in this quarter we have done almost 37% EBITDA margins and you know, we have always highlighted that our margins will remain around 25 to 30% for the combined business with oncology scaling up. So but this quarter we saw a significant improvement in margins for 30 of 37%. So what was the reason for the same and how do you see the margins for the company for FY27?
Unidentified Participant
So the margins like improvement in the margins, I would say that was more towards operational efficiencies and the major contribution to this came from the reduction in the cost of productions and as well as the various fixed expenses that we were incurring. The absorption rate has improved. So that has led to the improvement in the EBITDA margins and we look forward to have the same trend going forward.
Operator
Sorry to interrupt. May we request Mr. Gupta to please rejoin the queue? Thank you. The next question is from the line of Daniel Shah from Iwealth. Please go ahead.
Avnish Burman
Good afternoon sir. Congrats on a great side of numbers and thank you for the opportunity. Am I audible?
Rupesh Tatiya
Yeah, yeah, absolutely,
Avnish Burman
Yeah. Sir, just wanted to check on the gross margin which the earlier participant was also trying to understand. Right. I mean sequentially sir, if we see our oncology sales are pretty similar. 30, 31 North Cross. Right. So. So there is a gross margin increase of 10 11%. So was there any inventory benefit we got in this quarter particularly and I think that we were earlier guiding for a closer to a 40 crore run rate for this quarter and I think we’ve done only 31 odd crores. So if you can just explain that also.
Unidentified Participant
So for the margin part of it we would say that yes, the inventory part of it which we have been able to plan properly. So that has given the advantage on that as well. So the stocking pattern has improved. So that has also led to the efficiencies in terms of the cost which has come down and with respect to the sales part of it because it can throw some light on that.
Operator
Is that answer is your question, Mr. Shah?
Avnish Burman
Yeah, I mean I think the second part on the. On the oncology sales. I can’t hear you,
Bikramjit Ghosh
Just repeat your query.
Avnish Burman
I mean sir, on the oncology side I think we were earlier guiding to closer to 3840 crores for this quarter. But sequentially sir we’ve been flagged on that. Just wanted to understand what happened on that.
Bikramjit Ghosh
Just to make sure that we are on track only because there are certain processes which needs to be complied with. As I told you earlier in terms of exports because you can see that Already we have 12 registrations which we have received. Now in order to move ahead with this registration supplies so we need to have the number of processes aligned in terms of serialization of the product. Then we need to have certain artwork approvals, commercials, logistics, commercial purchase order logistics. Then we have the supply chain in place.
So the initial supply takes a little bit of time. Any anyway so, so whatever we may have planned for that is right on track. Maybe a little bit of few weeks here and there may have happened. But having said that as on date we have around 23 plus products which have already been submitted in different parts and we are expecting the registrations coming up maybe in few months time. So. So that will pump up the sales whatever we are looking forward to in the coming couple of quarters.
Avnish Burman
Sure. And so my, my second question is on the on the API integration. Right. I think for our for the exports to happen to the Europe, I believe that we haven’t yet got the approvals on the API block. Correct. So when do you all expect that to come in?
Bikramjit Ghosh
Yeah, right now, whatever the APIs we have developed in house, that is around 21 episodes in cytotoxic range. And definitely that will be the objective that we should backward integrate with all our products which are going commercially. So as an initial phase what we have already done is that we have already submitted four of our the CEP which is required when you are moving ahead for the regulated market in terms of integrated API supplies or finished formulation.
Unidentified Participant
Now
Bikramjit Ghosh
In that case already we have received two API with cep, Jefetinib and Cetera, the two products. So these two products right now we can integrate with our current formulation and we can export to all the regulated markets. Obviously emerging market is included in that. Apart from that, we have also planned for another two API with CEP which have been submitted and that also we are expecting maybe next couple of quarters. So that makes a tally of around 4 already applied to we have received and we have also planned for five more APIs we have identified which can be integrated properly.
This definitely is always based on the commercial visibility what we get from the market. So this file will then be submitted accordingly and roughly this takes around six months time. It may be a little more depending upon whatever the time you are submitting to the application. But in a net or summarized way, if I tell already we have got approval for two in terms of 21 APIs which we can right now move ahead for the regulated market. 2 are in process which can come account in next 2 months and rest 5 we are planning for in the coming few quarters so that we can make the tally total to 9 out of 21 which we have developed in house.
Got it sir,
Operator
Thank you. The next question is from the line of Disha from Sapphire Capital. Please go ahead.
Unidentified Participant
Hello, Am I audible sir?
Avnish Burman
Yeah, yeah,
Unidentified Participant
Yes. Thank you so much for this opportunity and congratulations sir for a great set of numbers. So as the previous part one of the previous participants is asked, so we’ve seen a meaningful improvement in our margin, then you highlighted the reasons why. So how should we look? So what are the base margins that we’re looking at for FY27 and as the oncology segment scales up, what are the steady state margins that we can expect at optimal level? Yeah, I said the margins we are expecting right now on the same levels that we have been able to Achieve.
But probably, yes, the margins would definitely improve as the contribution from the oncology improves. Because oncology gives better margin in comparison to the core business that we have. So exact numbers, probably we might not be able to tell right now, but yes, the trend would be almost increasing in the time to come. So this 27, 28% that we’ve done on a full year basis, that is sustainable, right? Yeah, that will be sustained, probably improved over that. Okay, and so how should we look at the tax rate for FY27?
For tax rate for the FY27, we would be moving into the normal tax rates going forward in FY27. So around 25, 25%. Yes. Okay. Okay, that is it for my slide. Thank you.
Operator
Thank you. The next question is from the line of Daniel Desai from Total Capital. Please go ahead.
Ishit Desai
Hi, good afternoon everyone and congratulations for a very good year. So my first question is, you know, we talked about the nine, you know, tech transfer with a code, you know, that is in the pipeline, out of which two we have already kind of got approved and we have started supplying. How should we look at the timeline in terms of the commercializing the rest 7, 8 products which are with the Accord. And typically once you get a tech transfer approval, what’s the timeline with which we should work in terms of commercial, you know, production and supply to the Accord?
Bikramjit Ghosh
Normally the tech transfer, as I mentioned, the seven products are on the pipeline right now. It has been submitted in EMA for the approval by the European Authority. So one by one they will be approved and we can start supplying them. So there is no access threshold time, but it’s the normal lead time. What basically is required because the product is already there in the market, so everything is ready in terms of artwork and everything. So they will just do a replica here at our facility based on the grant of this variation, what they have filed and approved so it can be supplied.
So there is no lack phase as such for this approved products which are basically coming from Accord. But having said that, the seven products will come one by one. Maybe we can expect one, one or two this quarter and maybe the following quarter the rest. So once this comes up, then we can start looking for the commercials from there.
Ishit Desai
Okay. Okay. And this 5200 crore number range that we have given from this business, is it contingent upon we getting all nine approvals or, you know, a certain number of approvals that we have factored in? And what is the risk of that sleeping away, you know, because of various regulatory reasons, you know, how should we look at that risk of not getting into that 5,200 crore number that we are factoring in.
Bikramjit Ghosh
The number is basically the number which we have derived based on the forecast of business plan, what we have received from Accord. But again that is a business plan and there is no binding focus on that. Nobody will give that. That is the practical thing. And Europe being a vast wider region, there are a number of countries in included in that. So estimation of the actual number is very difficult because the 28 countries coming into picture. But having said that, that is the reason why we have taken number of buffers and filters on that and we are pitching for 50 crore out of it.
So if any of the products sell less or any of the country off tax gets low still we will be achieving that number. So that is a full year number of 50 crore to 100 crore. What we can look forward to.
Ishit Desai
And the second question on the, you know, so total 100 crore delta that we are looking for the next year. Let’s say this year we did oncology 96. Next year maybe another 90, 200 crore. So out of that 50, 60 crore will come from, you know, the tech transfer part. The rest will come from our own brand those years which we, which we will launch in Europe. Is that understanding correct? And if so are we, are we already kind of, you know, we have got I think five approvals. So are we already commercializing any of that?
How should we see the scale up of our own brand registration in Europe to kind of get to that 100 crore additional number for FY27?
Bikramjit Ghosh
Yeah, as I mentioned earlier also the domestic business, whatever we are getting that will sustain the number and have its own growth based on the domestic right now growth of around 10% on the oncology segment. But having said that, the export growth will be primarily driven by this tech transfer project and our own registrations. What we are looking forward to that is the own registration means the exports. Basically that is the registration where we have licensed out the dossiers and partners have registered the product in the versus market.
So as I told you already, we have submitted 23 plus 8. So 31 dossiers have already been there in the market which are currently on the registration. And thereby we are expecting that maybe this calendar year or maybe this financial year, end this 31. So out of that if we expect also 80% coming in in terms of commercials because we need a commercial lead time of around 30, 120 to 150 days for the first supply. So if we consider that by quarter three we get around 80% of this registration also which roughly comes around pretty registrations.
So we will be commercializing these 25 products in this year, this financial year and that will boost up the sale. What of what we are mentioning earlier also that it will catch up the domestic sale from the export part considering the tech transfer and export of this registered products.
Operator
Thank you. The next question is from the line of Avnish permanent from Vikarya. Please go ahead.
Unidentified Participant
Hi, good afternoon. Thanks for taking my question. Bikrandi ji, just one question. On the 500 crore ambition that you outlayed for the next two years can you give some breakup on how this 500 crore is split between one oncology and non oncology and second within oncology how is it split between Onco exports and Onco domestic?
Bikramjit Ghosh
See the aspiration is 60 on go 40 the non onco because oncology power unit value is always higher and our means right now focus as well as the total setup what we have supports that. So we will run for that 60 plus from Oncology and in that also if we look forward to basically it will be again a breakoff of around maybe 65. 35 with 65% on the exports and 35% on the domestic.
Unidentified Participant
Hello. Am I audible? Hello.
Operator
Yes you are.
Unidentified Participant
Yeah Vikramji, you were saying 65% export and 35% domestic. Did I hear that right?
Bikramjit Ghosh
Yeah, yeah, right.
Unidentified Participant
Okay. Okay. My second question was on the. On the cost increases that the business might be seeing because of the Middle east conflict. And this could be from various angles either raw material or RMPM or you know, freight costs, insurance costs, whatever the case might be. How are you handling that? Are you passing it on to the customers or are you part passing it, part absorbing it? If you could just throw some light on that.
Bikramjit Ghosh
The first part is that we do not have that much of dependency on the mid list in terms of our present business. Or maybe the business setup what we have for Oncology also the stick on that part is significantly less. The second part is that yes, obviously if something is happening there in Middle east the impact may come over indirectly to us in terms of API or logistic or something else. For that we have already the business contract saying that if there is a significant increase after a certain level we will be passing on to the partners regarding the same.
So we are well protected from that part as on date.
Unidentified Participant
Okay, thanks. I have a couple more but I’ll get back.
Operator
Thank you ladies and gentlemen. That was the last question for today. With that I now hand the conference over to management for closing comments.
Avnish Burman
Thank you everyone, for joining the SACCA Healthcare Financial 26 conference speech. Thank you so much.
Operator
Thank you. Ladies and gentlemen, on behalf of Sakar Healthcare Limited, that concludes this conference. Thank you for joining us. And you may now connect your lines.